EVŌQ Nano engineers’ and develops novel nanoparticles for the life, and textile science industries.
Nanoparticles for Health and Textiles
The company has been developing an inhaled therapeutic using the nanoparticle EVQ-218 that is used to treat pulmonary bacterial infections for cystic fibrosis patients.
EVŌQ Nano also plans to create products or medical devices called EVŌQ MedTech. This uses EVQ-218's antimicrobial capabilities on medical devices to defend against a broad spectrum of contaminants like bacteria and fungi.
Innovative Microbial Treatments
In addition, the company will deliver a microbial treatment called Fuze Technologies which serves the textile industries with its antimicrobial technology that is chemical-free. #EVŌQ Nano's antimicrobial nanoparticle platform has demonstrated effectiveness against the WHO's top six antibiotic-resistant bacterial strains without triggering resistance.
Robbins’ Investment and Partnership
"I've always looked to support innovative advancements in health technology, and EVŌQ Nano's approach to fighting antibiotic-resistant bacteria addresses an urgent global challenge," said Mr. Robbins. "This game-changing technology has the potential to save millions of lives and transform how we approach infection prevention and treatment."
Robbins will also serve on the company's advisory board.
A Significant Milestone for EVŌQ Nano
"Having Mr. Robbins join us as both an investor and strategic partner marks a significant milestone in EVŌQ Nano's journey," said Shaun Rothwell, CEO of EVŌQ Nano. "Mr. Robbins' global reach, business acumen, and passion for improving lives align perfectly with our mission. His support will be instrumental in advancing the development of our pioneering technology."
